Centiva Capital, LP
Institutional investor · Portfolio as of Q1 2019
Top Holdings306 positions
SPDR S&P 500 ETF TR | 588,600 | $166.3M | 11.2% | — | — | — | First report — |
ALTABA INC | 2.2M | $165.9M | 11.2% | — | — | 1 qtr | First report 0 |
INVESCO QQQ TR | 784,600 | $141M | 9.5% | — | — | — | First report — |
ISHARES TR | 672,500 | $103M | 6.9% | — | — | — | First report — |
SPDR S&P 500 ETF TR | 252,300 | $71.3M | 4.8% | — | — | — | First report — |
INVESCO QQQ TR | 319,500 | $57.4M | 3.9% | — | — | — | First report — |
ISHARES TR | 312,000 | $47.8M | 3.2% | — | — | — | First report — |
COTY INC | 2M | $22.6M | 1.5% | — | — | — | First report — |
VANECK ETF TRUST | 850,000 | $19.1M | 1.3% | — | — | — | First report — |
ALIBABA GROUP HLDG LTD | 103,200 | $18.8M | 1.3% | — | — | — | First report — |
REGENERON PHARMACEUTICALS | 42,300 | $17.4M | 1.2% | — | — | — | First report — |
ALPHABET INC | 13,200 | $15.5M | 1.0% | $58.29 | 0.00% | 1 qtr | First report 0 |
MICRON TECHNOLOGY INC | 339,400 | $14M | 0.9% | — | — | — | First report — |
ISHARES TR | 312,500 | $13.8M | 0.9% | — | — | — | First report — |
VANECK ETF TRUST | 613,800 | $13.8M | 0.9% | — | — | — | First report — |
AMAZON COM INC | 6,600 | $11.7M | 0.8% | — | — | — | First report — |
SPDR GOLD TR | 89,990 | $11M | 0.7% | $122.01 | 0.00% | 1 qtr | First report 0 |
SELECT SECTOR SPDR TR | 188,189 | $10.9M | 0.7% | $23.07 | 0.00% | 1 qtr | First report 0 |
ALTABA INC | 146,600 | $10.9M | 0.7% | — | — | — | First report — |
PAYPAL HLDGS INC | 98,900 | $10.3M | 0.7% | — | — | — | First report — |
Centiva Capital, LP manages $1.5B across 306 positions as of Q1 2019. Top holdings: SPY puts (11.2%), AABA (11.2%), QQQ puts (9.5%). Fund DNA: Momentum Trader. HoldingsIntel Score: 1/5.0.
First quarter we have for this fund: 306 positions, nothing earlier to compare. No standout high-conviction moves this quarter. Portfolio: $1.5B across 306 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR